BR112022013978A2 - Peptídeo isolado, e, composição farmacêutica - Google Patents
Peptídeo isolado, e, composição farmacêuticaInfo
- Publication number
- BR112022013978A2 BR112022013978A2 BR112022013978A BR112022013978A BR112022013978A2 BR 112022013978 A2 BR112022013978 A2 BR 112022013978A2 BR 112022013978 A BR112022013978 A BR 112022013978A BR 112022013978 A BR112022013978 A BR 112022013978A BR 112022013978 A2 BR112022013978 A2 BR 112022013978A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- isolated peptide
- isolated
- dexamethasone
- mouse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL272074A IL272074B2 (en) | 2020-01-15 | 2020-01-15 | Peptide compounds and methods of treating diseases using same |
| PCT/IL2021/050044 WO2021144798A1 (en) | 2020-01-15 | 2021-01-14 | Peptide compounds and methods of treating diseases using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013978A2 true BR112022013978A2 (pt) | 2022-10-11 |
Family
ID=76863930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013978A BR112022013978A2 (pt) | 2020-01-15 | 2021-01-14 | Peptídeo isolado, e, composição farmacêutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230049549A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4090347A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7809060B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220145826A (cg-RX-API-DMAC7.html) |
| CN (6) | CN119708143A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021207415B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013978A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167139A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022011101A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272074B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008746A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021144798A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7395517B2 (ja) | 2018-07-11 | 2023-12-11 | イミュニティ ファルマ リミテッド | ペプチド化合物およびその治療的用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| WO2003037172A2 (en) * | 2001-11-01 | 2003-05-08 | Gpc Biotech Inc. | Endothelial-cell binding peptides for diagnosis and therapy |
| AU2005276117C1 (en) * | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| US8648045B2 (en) * | 2005-03-10 | 2014-02-11 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | VDAC1 compositions and methods of use thereof for regulating apoptosis |
| EP2331564A4 (en) * | 2008-10-06 | 2013-02-20 | Carolus Therapeutics Inc | PROCESS FOR TREATMENT OF IGNITION |
| US20130096070A1 (en) * | 2009-04-07 | 2013-04-18 | University Of Kansas | Peptide targeting of inner ear cells |
| EP3263127B1 (en) * | 2011-05-23 | 2019-08-21 | Yeda Research and Development Co. Ltd | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| CA3172682A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| JP7395517B2 (ja) * | 2018-07-11 | 2023-12-11 | イミュニティ ファルマ リミテッド | ペプチド化合物およびその治療的用途 |
-
2020
- 2020-01-15 IL IL272074A patent/IL272074B2/en unknown
-
2021
- 2021-01-14 US US17/792,787 patent/US20230049549A1/en active Pending
- 2021-01-14 CN CN202411888873.0A patent/CN119708143A/zh active Pending
- 2021-01-14 EP EP21704023.7A patent/EP4090347A1/en active Pending
- 2021-01-14 MX MX2022008746A patent/MX2022008746A/es unknown
- 2021-01-14 CN CN202411888870.7A patent/CN119708142A/zh active Pending
- 2021-01-14 CN CN202411888865.6A patent/CN119708140A/zh active Pending
- 2021-01-14 WO PCT/IL2021/050044 patent/WO2021144798A1/en not_active Ceased
- 2021-01-14 CN CN202411888874.5A patent/CN119708144A/zh active Pending
- 2021-01-14 CN CN202411888869.4A patent/CN119708141A/zh active Pending
- 2021-01-14 BR BR112022013978A patent/BR112022013978A2/pt unknown
- 2021-01-14 KR KR1020227028077A patent/KR20220145826A/ko active Pending
- 2021-01-14 AU AU2021207415A patent/AU2021207415B2/en active Active
- 2021-01-14 CA CA3167139A patent/CA3167139A1/en active Pending
- 2021-01-14 CN CN202180017719.4A patent/CN115942948B/zh active Active
- 2021-01-14 JP JP2022542986A patent/JP7809060B2/ja active Active
-
2022
- 2022-08-04 CO CONC2022/0011101A patent/CO2022011101A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL272074B2 (en) | 2024-12-01 |
| CO2022011101A2 (es) | 2022-11-08 |
| CN119708143A (zh) | 2025-03-28 |
| IL272074B1 (en) | 2024-08-01 |
| MX2022008746A (es) | 2022-10-13 |
| CN119708142A (zh) | 2025-03-28 |
| IL272074A (en) | 2021-07-29 |
| CN119708141A (zh) | 2025-03-28 |
| CN115942948B (zh) | 2025-01-14 |
| CN115942948A (zh) | 2023-04-07 |
| EP4090347A1 (en) | 2022-11-23 |
| JP2023510019A (ja) | 2023-03-10 |
| US20230049549A1 (en) | 2023-02-16 |
| CN119708144A (zh) | 2025-03-28 |
| AU2021207415A1 (en) | 2022-09-08 |
| KR20220145826A (ko) | 2022-10-31 |
| AU2021207415B2 (en) | 2026-08-13 |
| WO2021144798A1 (en) | 2021-07-22 |
| JP7809060B2 (ja) | 2026-01-30 |
| CN119708140A (zh) | 2025-03-28 |
| CA3167139A1 (en) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| CL2011000086A1 (es) | Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b. | |
| BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| FI3421486T3 (fi) | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi | |
| BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
| BR112018072264A2 (pt) | composição farmacêutica | |
| BR112019023260A2 (pt) | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
| BR112019008349A2 (pt) | composição de peptídeos, e, utilização de uma composição. | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| BR112023019138A2 (pt) | Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso | |
| BR112021006280A2 (pt) | terapias imunoablativas | |
| BR112021026292A2 (pt) | Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria | |
| MX2022006426A (es) | Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80. | |
| BRPI0418304A (pt) | peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv | |
| BR112022007776A2 (pt) | Composições e métodos para minimizar a perda de proteína em baixas concentrações de proteína |